Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam | Zendy

Mohamad Yasmin | Zendy; Jennifer Hanrahan | Zendy; Steven Marshall | Zendy; Thomas P. Lodise | Zendy; Liang Chen | Zendy; Federico Pérez | Zendy; Barry N. Kreiswirth | Zendy; Robert A. Bonomo | Zendy

Open Access

Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam

Author(s) -

Mohamad Yasmin,

Jennifer Hanrahan,

Steven Marshall,

Thomas P. Lodise,

Liang Chen,

Federico Pérez,

Barry N. Kreiswirth,

Robert A. Bonomo

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa349

Subject(s) - klebsiella pneumoniae , medicine , ceftazidime/avibactam , ceftazidime , bacteremia , meningitis , cerebrospinal fluid , microbiology and biotechnology , antibiotics , pseudomonas aeruginosa , surgery , biology , bacteria , escherichia coli , biochemistry , genetics , gene

This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)–3–producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC– Klebsiella pneumoniae central nervous system infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research